Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of a patient at risk.
We are working on deep learning algorithms enabling the prediction and prevention of acute coronary events.
We are working on deep learning algorithms enabling the prediction and prevention of acute coronary events.
Location: Australia, Western Australia, Perth
Employees: 11-50
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Alium Capi... | aliumcap.c... |
Mentions in press and media 2
| Date | Title | Description |
| 21.08.2025 | FDA clearance of Salix® Coronary Plaque module | Significantly expands U.S. commercial opportunity with ability to charge fees per scan assessed Investor Webinar - 11.30am AEST (9.30am AWST) on 22 August 2025 PERTH, Australia, Aug. 21, 2025 /PRNewswire/ -- Artrya Limited (ASX: AYA) (Artry... |
| - | Remote monitoring for coronary artery disease patients gets $5M from CMS | A remote monitoring program by University of Pennsylvania Health System to better track patients hospitalized for acute myocardial infarction once they are discharged has received $4.8 million in funding from the Centers for Medicare & ... |